QR-koodi

Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C797S mutation is a commo...

Täydet tiedot

Tallennettuna:
Päätekijät: Wenting Lu, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, Yalun Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2025-03-01
Sarja:Current Oncology
Aiheet:
NSCLC
<i>EGFR</i> mutation
<i>EGFR</i>-TKI
osimertinib
gefitinib
bevacizumab
Linkit:https://www.mdpi.com/1718-7729/32/4/201
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia